UNCY unicycive.com: Rasio nilai perusahaan marang pendapatan

Simbol resmi perusahaan unicycive.com (UNCY)

Unicycive Therapeutics (UNCY) generates revenue from the therapy of dialysis patients with renal failure. The price-to-sales ratio on GURU.Markets reflects market expectations, where the 0.00 metric indicates the asset's status. The business foundation relies on outsourced production via CDMOs, while patent protection and FDA requirements create a robust defensive barrier for the monopolist.

UNCY Unicycive Therapeutics: Multiplikator EV/Sales ing interval 23.11.2025 - 20.11.2026

Unicycive Therapeutics, Inc - rincian analitis lan metrik utama (UNCY)

- kuotasi saiki lan rata-rata prakiraan nilai:
- data kapitalisasi saham perusahaan:
- data saldo dhuwit lan arus kas:
Pambiji fundamental perusahaan:UNCY (Unicycive Therapeutics, Inc.)
Barang utama Unicycive

This ratio determines the investment attractiveness of Unicycive Therapeutics (UNCY) by comparing the Enterprise Value to annual revenue, excluding debt load. By analyzing the company's value-to-revenue dynamics, an investor can discern market expectations for the commercialization of Renazorb for the treatment of hyperphosphatemia, where sharp peaks in the indicator signal an overvaluation of future successes in the nephrology segment.